Because PAH can be severe and often challenging to treat, it can lead to severe short- and long-term health challenges. Read on to learn more about the medications available to treat PAH ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Of these groups, pulmonary arterial hypertension (PAH) is the most studied and, therefore, all of the currently available drug classes (prostacyclin analogs, endothelin receptor antagonists and ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

It was founded in 2015 and develops therapies for pulmonary hypertension [PH]. Currently, GOSS’ leading drug is Seralutinib, previously called GB002, a tyrosine kinase inhibitor for PH.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...

Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of ...